A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on)
Clinical trial NCT02250027 · COMPLETED
Trial details
- NCT number
- NCT02250027
- Sponsor
- Hanlim Pharm. Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-01
- Primary completion
- 2014-07-01
- Enrollment
- 156
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.